Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The simultaneous determination of acid phosphatase and citrate concentration in the seminal fluid obtained from 16 patients with prostatic adenoma showed normal values, 6 patiients with prostatic carcinoma (cytologically and histologically verified) however extremely low values. The difference between persons with prostatic cancer and those with adenoma became particulary obvious with both experimental results evaluated in the way of a twodimensional diagram. This clear separation of both clusters by the simultaneouse estimation of both biochemical parameters may possible get useful diagnostic significance.
 ...
PMID:[Citrate and acid phosphatase in the ejaculate in prostatic carcinoma and adenoma]. 8 Oct 63

The epididymal penetration of roxithromycin was studied in order to evaluate the drug for use in the treatment of epididymo-orchitis. Seventeen patients hospitalized for surgery as part of treatment for prostatic adenoma or prostatic cancer were premedicated orally with roxithromycin 150 mg bd for three days followed by 150 mg pre-operatively (3 h before surgical incision). Roxithromycin concentrations in serum and epididymis were determined by microbiological assay. The mean epididymal concentrations were 6.48 +/- 4.88 and 5.98 +/- 3.92 mg/kg for left and right epididymis respectively and the corresponding mean tissue/serum ratios 0.88 +/- 0.57 and 0.84 +/- 0.53. The wide intersubject variation in the concentration of roxithromycin found in serum and tissue is commonly seen with other macrolide antibiotics. The concentrations observed in this study in serum and tissue were greater than the MIC90s for Chlamydia trachomatis (0.25 to 1 mg/L), and Ureaplasma urealyticum (0.5 mg/L).
 ...
PMID:Disposition of roxithromycin in the epididymis after repeated oral administration. 139 28

Immunochemical tests were employed to measure proteins (acid phosphatase, prostatic beta-globulin, endometrial alpha-2-globulin, lactoferrin, carcinoembryonal antigen) in spermatic plasma and prostatic fluid from healthy subjects and patients with prostatic adenoma, cancer, chronic inflammation, defects of spermatogenesis. It was found that the overall concentration of acid phosphatase and prostatic beta-globulin may serve a diagnostic criteria to differentiate prostatic adenoma from cancer as in 93% of prostatic cancer this parameter did not exceed 400 micrograms/ml whereas in 75% of adenomas it was above 1200 micrograms/ml. Activity of chronic prostatitis can be assessed from lactoferrin test. The level of the organ-specific antigens (acid phosphatase and prostatic beta-globulin) and lactoferrin correlated with the severity of spermatogenesis disorders.
 ...
PMID:[Immunochemical tests in the diagnosis of diseases of the male reproductive system]. 175 26

Norfloxacin, a "second generation" compound of the quinolone group, was administered orally, before surgery, every 12 h during successive three-day periods at dose of 400 mg to ten patients hospitalized for prostatic adenoma or for prostatic cancer. On the day of surgery, a 400 mg-last dose was administered. Unchanged norfloxacin was assayed by high performance liquid chromatography with fluorescence detection. The Cmin value was 1.2 +/- 0.77 mg/l. Concurrent norfloxacin concentrations in plasma and epididymal tissue (left and right) were determined, about 4 h after the last drug intake, the epididymal level was 3.4 +/- 1.9 micrograms/g. This value was above the MIC90 for most sensitive organisms. The ratio (+/- SD) of drug concentration in epididymal tissue and in plasma was 3. 74 +/- 2.10 (range 1.66-10.2). The epididymal level of norfloxacin was strongly correlated with, area under curve (p less than 0.001) and plasma concentration (p less than 0.01).
 ...
PMID:[Diffusion of norfloxacin in epididymal tissue]. 188 87

In search of a suitable histological material handling method to record the whole number of incidental prostatic cancers, which deal with the personnel situation of a routine laboratory, the so-called 5-g-rule was evaluated in 100 cases of prostatic adenoma material. Subsequently the rest material was checked completely. A further control material were 480 irregular reviewed prostatic adenoma specimens. By the use of the 5-g-rule the frequency of prostatic cancer was increased from 6.9% to 10%. In the rest material further 9 carcinomas and much more inflammatory, atrophic and atypical-hyperplastic lesions were found. However, the 5-g-rule is for an experienced pathologist a good screening method to find the majority of carcinomas.
 ...
PMID:[Effect of histologic specimen preparation on the frequency of incidental prostatic cancer]. 247 90

The blood levels of hydroxycorticosteroid-11 (11-HOCS) before and after dexamethasone, somatomedins, cholesterol, triglycerides, beta-lipoproteins and cholesterol of high-density lipoproteins were studied in 55 patients with prostatic adenoma and 75 cases of prostatic cancer. It was found that the hypothalamo-pituitary system is resistant to inhibition by dexamethasone in both groups, while elevation of absolute level of 11-HOCS was observed in cases of adenoma. Patients with prostatic cancer revealed a higher blood serum-somatomedin level. Triglyceride level was relatively higher, and diabetes mellitus and hyperlipidemia (type IIb and IV) were slightly more frequent in patients with prostatic adenoma. This was matched by a relatively higher level of cholesterol and more frequent hyperlipidemia type IIa in cancer patients.
 ...
PMID:[Dexamethasone test, somatomedin level and other metabolic indices in adenoma and cancer of the prostate]. 618 84

The usefulness of a new specific immunoenzymatic assay for the prostatic acid phosphatase for diagnosis and monitoring of prostatic carcinoma has been investigated. The results include 200 healthy men without urologic anamnesis, 50 patients suffering from prostatic adenoma, and 152 patients with prostatic carcinoma. Out of 152 patients with prostatic carcinoma 110 were so-called therapy-responders and 42 were patients with progression of prostatic cancer. The immunoenzymatic assay for PAP shows good results for the separation of patients with progressive prostatic carcinoma, from those patients with a stationary prostatic cancer as well as for monitoring of prostatic carcinoma. The diagnostic value of the test has been found significantly higher than that of previous tests with different substrates. As this method allows the direct measurement of the activity of the specific prostatic acid phosphatase in U/l there is no need to run a standard-curve. It is recommended to use different "normal ranges" for patients with and without therapy. For monitoring mainly intraindividual studies are requested.
 ...
PMID:[Significance of an immunoenzyme assay of the prostate-specific acid phosphatase (PAP) (E.C.3.1.3.2.) in prostatic carcinoma. Methods and initial clinical results]. 619 96

The authors begin by stressing the importance of the role of prolactin in the metabolism of testosterone in the cells of the prostate. They studied three groups of patients: 9 patients with prostatic cancer, 15 patients with benign prostatic adenoma and 11 healthy young men. Inhibition of the dopaminergic receptors by metoclopramide only resulted in a significant increase in serum prolactin in the patients with prostatic cancer, while the serum prolactin level remained unchanged in the young men and in the patients with prostatic adenoma. The authors believe that this increased secretion of prolactin in patients with prostatic cancer is related to a decrease in the testosterone: oestradiol ratio. They suggest the use of bromocriptine in patients with prostatic cancer no longer responding to oestrogen therapy in the event of prolactin over-secretion. Some papers have reported the beneficial effect of bromocriptine on the general health of these patients.
 ...
PMID:[Increased secretion of prolactin after inhibition of dopaminergic receptors by metoclopramide in patients with cancer of the prostate]. 620 86

This paper presents a survey of the factors implicated or suspected of involvement in the occurrence of prostatic cancer. Influences of age, racial and geographical factors, time trends, socioeconomic and sexual factors, venereal diseases, heredity, environmental factors, prostatic adenoma, associated diseases, virus and endocrine status are reviewed. Except for age, race and possible but not well defined local and environmental factors, very little is known about the causes favouring the development of the disease. The author stresses the importance of collaborative studies to improve our knowledge of this common cancer.
 ...
PMID:Etiological and epidemiological considerations in prostatic cancer. 693 42

Correct forecasting of prostatic carcinoma by means of serum PSA is limited. Prostatic carcinoma is said to increase PSA 10 times as much as prostatic adenoma. Therefore we evaluated whether PSA in the prostatic fluid is more specific for prostatic carcinoma than the level in the serum. In 31 consecutive patients with prostatic disease blood was taken for serum PSA first and then prostatic fluid (10 microliters) was expressed. The PSA was determined by the Pros-Check test in both the serum and in the prostatic fluid. The collection of the prostatic fluid failed in 7 (22.6%) patients. Of the remaining 24 patients, 5 had documented bacterial prostatitis, 4 had prostatic carcinoma and 15 had benign prostatic hyperplasia (BPH). The serum PSA was 5.6 +/- 5.0 micrograms/l in prostatitis, 148 +/- 208 micrograms/l in prostatic carcinoma and 6.9 +/- 6.8 micrograms/l in BPH. The serum PSA was significantly higher in prostatic cancer (P < or = 0.01) than in prostatitis and BPH. The PSA levels in the prostatic fluid were 14.0 +/- 25.7 x 10(6) micrograms/l in prostatitis, 7.6 +/- 9.7 x 10(6) micrograms/l in carcinoma and 14.0 +/- 14.6 x 10(6) micrograms/l in BPH. There were no statistically significant differences. In the expressed prostatic fluid no significantly different PSA was found in carcinoma, bacterial prostatitis or BPH. In contrast to this, the serum PSA was significantly higher in cancer patients than in prostatitis or BPH. Therefore PSA in the expressed prostatic fluid is no more specific than that in the serum.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[PSA in prostatic fluid]. 751 4


1 2 3 Next >>